ERBB2 and endometrial cancer: This knowledge provided a potential molecular explanation to the failure of previous NRG/NCI cooperative clinical trials targeting endometrial cancer patients with single-agent trastuzumab (a humanized monoclonal antibody targeting HER2/neu)22.